Glecaprevir/pibrentasvir for hepatitis C virus genotype 3 patients with cirrhosis and/or prior treatment experience: A partially randomized phase 3 clinical trial.
about
Effectiveness of current and future regimens for treating genotype 3 hepatitis C virus infection: a large-scale systematic review.Glecaprevir + pibrentasvir (ABT493 + ABT-530) for the treatment of Hepatitis C.Recent update of the 2017 Korean Association for the Study of the Liver (KASL) treatment guidelines of chronic hepatitis C: comparison of guidelines from other continents, 2017 AASLD/IDSA and 2016 EASL.Hepatitis C virus genotype 3: clinical features, current and emerging viral inhibitors, future challengesGlecaprevir/pibrentasvir for hepatitis CPooled Resistance Analysis in Patients with Hepatitis C Virus Genotype 1 to 6 Infection Treated with Glecaprevir-Pibrentasvir in Phase 2 and 3 Clinical Trials
P2860
Glecaprevir/pibrentasvir for hepatitis C virus genotype 3 patients with cirrhosis and/or prior treatment experience: A partially randomized phase 3 clinical trial.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
Glecaprevir/pibrentasvir for h ...... omized phase 3 clinical trial.
@en
type
label
Glecaprevir/pibrentasvir for h ...... omized phase 3 clinical trial.
@en
prefLabel
Glecaprevir/pibrentasvir for h ...... omized phase 3 clinical trial.
@en
P2093
P2860
P50
P356
P1433
P1476
Glecaprevir/pibrentasvir for h ...... omized phase 3 clinical trial.
@en
P2093
Benedict Maliakkal
Chih-Wei Lin
Federico J Mensa
Franco Felizarta
Frank Weilert
Kosh Agarwal
Paul Y Kwo
Preethi Krishnan
P2860
P356
10.1002/HEP.29541
P407
P577
2017-09-19T00:00:00Z